These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 1552875)

  • 1. [Growth velocity in thalassemic children receiving different protocols of chelating therapy].
    Elena MG; Fedele A; Gianino P; Giordanino S; Murru P; Tosi C; Vannelli S
    Minerva Pediatr; 1992; 44(1-2):41-2. PubMed ID: 1552875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 3. Growth velocity monitoring of the efficacy of different therapeutic protocols in a group of thalassaemic children.
    Benso L; Gambotto S; Pastorin L; Signorile F; Tanner JM
    Eur J Pediatr; 1995 Mar; 154(3):205-8. PubMed ID: 7758518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
    Gaini RM; Moretti E; Boffa C; Terzoli S; Carnelli V
    Pediatr Med Chir; 1988; 10(5):503-4. PubMed ID: 3241755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
    Gaziev J; Sodani P; Polchi P; Andreani M; Lucarelli G
    Ann N Y Acad Sci; 2005; 1054():196-205. PubMed ID: 16339666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Longitudinal growth of patients with homozygote beta-thalassemia during continuous subcutaneous infusion of deferoxamine].
    Krüger N; Stubbe P; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1986 Jan; 111(5):176-81. PubMed ID: 3943469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
    Rodríguez Galindo C; Ortega Aramburu JJ; Alonso JL; Albisu M; Casaldáliga J; Díaz de Heredia C; Olivé T; Bastida P
    Med Clin (Barc); 1994 May; 102(19):721-4. PubMed ID: 8041200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T; Ferro G; Frontini V; Percolla S
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive long-term intravenous iron-chelation therapy with deferoxamine in thalassemic patients.
    Cianciulli P; Forte L; Sorrentino F; Palombi M; Papa G; Marciani MG
    Bone Marrow Transplant; 1993; 12 Suppl 1():5-8. PubMed ID: 8374563
    [No Abstract]   [Full Text] [Related]  

  • 12. The treatment of Cooley's anemia.
    Nathan DG
    Haematologica; 1990; 75 Suppl 5():57-65. PubMed ID: 2086382
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
    Hathirat P; Isarangkura P; Areekul S; Pleehachinda R; Tuntawiroon M
    Birth Defects Orig Artic Ser; 1988; 23(5B):129-33. PubMed ID: 3390535
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desferrioxamine: its use in iron chelation in thalassemia.
    Sharma BK; Choudhury P; Dubey AP
    Indian Pediatr; 1990 Mar; 27(3):314-9. PubMed ID: 2190932
    [No Abstract]   [Full Text] [Related]  

  • 16. [Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)].
    Lévy G; Bachelot C; Joannard A; Bost M
    Arch Fr Pediatr; 1980 May; 37(5):299-303. PubMed ID: 7469704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A; Mizanin J; Schwartz E
    Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
    [No Abstract]   [Full Text] [Related]  

  • 18. [Echocardiographic measurements in transfused thalassemic major children].
    Balducci G; Antonelli GF; Mautone A; Di Lecce A; Schettini F
    Minerva Pediatr; 1980 May; 32(9):583-7. PubMed ID: 7464753
    [No Abstract]   [Full Text] [Related]  

  • 19. [Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
    Bachelot C; Plantaz D
    Pediatrie; 1990; 45(9):619-23. PubMed ID: 2175425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens.
    Viprakasit V; Tanphaichitr VS; Mahasandana C; Assteerawatt A; Suwantol L; Veerakul G; Kankirawatana S; Pung-Amritt P; Suvatte V
    J Med Assoc Thai; 2001 Jul; 84(7):929-41. PubMed ID: 11759973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.